FABP4 and lymphedema: Nevertheless, given its dual role in promoting cancer proliferation and contributing to lymphedema, FABP4 inhibition represents a compelling therapeutic strategy with the potential to address both cancer-related lymphedema and the metabolic alterations associated with cancer progression.